Analyst Jason McCarthy from Maxim Group maintained a Buy rating on Actinium Pharmaceuticals and keeping the price target at $5.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Jason McCarthy has given his Buy rating due to a combination of factors related to Actinium Pharmaceuticals’ promising pipeline and recent developments. The company is set to present encouraging preclinical data for its ATNM-400 candidate, which has shown potential in treating non-small cell lung cancer (NSCLC) with EGFR mutations, particularly in tumors resistant to existing therapies like osimertinib. Additionally, ATNM-400 has demonstrated efficacy in prostate cancer models that are resistant to standard-of-care therapies, highlighting its potential as a novel treatment option.
Furthermore, Actinium’s broader pipeline, including Actimab-A for acute myeloid leukemia (AML), is progressing with pivotal trials expected to start by the end of 2025. The company’s innovative approach, utilizing Actinium-225 for targeted radiotherapy, offers a unique mechanism of action that could provide improved tumor selectivity and reduced toxicity. These factors, combined with strategic plans for commercialization and partnerships, underpin McCarthy’s optimistic outlook and Buy rating for Actinium Pharmaceuticals.
ATNM’s price has also changed moderately for the past six months – from $1.320 to $1.560, which is a 18.18% increase.